Biomarker Linked to Pain Block Treatment Response
Researchers identified a potential blood marker to help predict how patients with complex regional pain syndrome respond to nerve blocks.
Updated on Sept. 29, 2026 in Stroke
Live Poll
Should preliminary research findings influence patient treatment expectations before large-scale validation is completed?
A small study of 20 patients found that higher baseline levels of the biomarker miR-21-5p may indicate a better response to lumbar sympathetic ganglion blocks for complex regional pain syndrome. This could eventually help clinicians better predict which patients are likely to benefit from this specific procedure.
Why it matters
Identifying reliable predictors is critical because there are currently no standard biomarkers to determine if a patient will respond to this type of nerve block. This research aims to move treatment toward a more personalized approach for those living with chronic pain.
In a study of 20 patients, researchers used a 768-target quantitative polymerase chain reaction array to compare plasma samples collected over three weeks. The findings, which identified miR-21-5p as a potential marker, remain preliminary and warrant further validation in larger cohorts.
The details
Researchers measured plasma samples at baseline, one week, and three weeks to analyze miRNA expression using a 768-target PCR array. Patients were defined as responders if they reported a 30% reduction in pain scores on the Numeric Rating Scale following a lumbar sympathetic ganglion block. While responders showed higher starting levels of miR-21-5p, non-responders demonstrated significant increases in both miR-21-5p and miR-625-5p levels over the three-week period.
Timeline
Baseline (T0) samples were obtained from participants.
Follow-up plasma samples and pain assessments occurred at 1 week (T1).
Final plasma samples were collected at 3 weeks (T2).
Health Landscape
This research contributes to the ongoing search for precision medicine biomarkers in chronic pain management. It represents a shift from symptom-based treatment toward biological indicators that may eventually allow clinicians to tailor interventions to individual patient profiles.
If you are considering a lumbar sympathetic ganglion block for chronic pain, this study highlights an emerging area of research that may one day inform your care. It is a topic worth discussing with your pain specialist to understand if current testing options exist for your specific condition.
The takeaway
While this study provides a promising lead in understanding why some patients respond to nerve blocks better than others, the findings are currently preliminary. Patients should continue to work closely with their medical team to evaluate the best diagnostic and treatment plan for their needs.
Further reading
For more information on the latest research and diagnostic developments, visit our Stroke section.
Source note: This article includes information reported by Nature.
Live Poll
Should preliminary research findings influence patient treatment expectations before large-scale validation is completed?
